<DOC>
	<DOCNO>NCT00159263</DOCNO>
	<brief_summary>To investigate possible interaction formoterol budesonide GR-translocation compare effect different dos Symbicort ( 80/4.5 2x80/4.5 mcg ) effect budesonide ( 200 mcg 800 mcg ) GR translocation , investigate effect study drug exhale NO ( bronchial alveolar fraction .</brief_summary>
	<brief_title>Effect Symbicort GR Localisation Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients mild steroidnaïve asthma ( ATS criterion ) either sex FEV1 &gt; 70 % pred Able produce sputum sputum induction Exhaled NO ( flow 50 ml/s ) ≥ 20 ppb Written inform consent Current upper respiratory tract infection Use inhale and/or oral GCS within 4 week prior visit 1 Treatment antileukotrienes , theophylline , tiotropium ipratropium within 2 week prior screen visit Hypersensitivity investigational drug lactose Use blocking agent ( include eyedrop ) Women pregnant , breastfeed plan pregnancy study . Women must postmenopausal ( least one year must pass last menstruation ) , surgically sterile use acceptable contraceptive , judge investigator Any significant disease disorder ( e.g . cardiovascular , pulmonary ( asthma ) , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , opinion investigator , may either put subject risk participation study , may influence result study , subject ability participate study Inability tolerate temporary withdrawal bronchodilatory therapy Subjects consider capable , judged investigator , follow instruction study , e.g . history alcohol drug abuse reason Previous randomization study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>